Build status - In Progress
Research Study on Whether a Combination of 2 Medicines Works in People With Non-alcoholic Steatohepatitis (NASH)
Recruiting
18 years - 99 years
All
Phase
N/A
75 participants needed
1 Location
Brief description of study
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. It also helps with weight loss and may reduce liver damage, and so prevent future liver complications. It works in a different way to NNC0194 0499. The 2 medicines may work better together than on their own.
The study will also look at a combination of semaglutide and another weight-loss medicine called NNC0174-0833, which may be another treatment option for NASH.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Non-alcoholic Steatohepatitis,NASH
-
Age: 18 years - 99 years
-
Gender: All
Male or Female Age 18 or older Histological evidence of NASH
Updated on
04 Aug 2024.
Study ID: 849168
Find a site
,
Your Information has been sent successfully.
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study
Select a study center that’s convenient for you, and get in touch with the study team.
Contact a study centerPlease choose between Voice or SMS based delivery of verification code
or